C.R. Jackson
Biotech, healthcare, value, research analyst

NuPathe Takes Investors Down A Bumpy Road

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

Three years ago, there were high hopes for NuPathe Inc. (PATH), a specialty pharmaceutical company that develops therapeutics for neurological and psychiatric disorders. NuPathe went public on August 6, 2010. Shares reached $10.22, an all-time high on the first day of trading. Unfortunately, the company's shares have traded down, way down to reach a low of $1.57 on October 22, 2013. Since then, the stock has slowly but steadily increased to over $2 a share.

NuPathe has the only US Food and Drug Administration (FDA) approved migraine patch, Zecuity (sumatriptan). Zecuity is a single-use, battery-powered patch that actively delivers ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details